FOR IMMEDIATE RELEASE

Tuesday, March 1, 2022

FDA APPROVES FURTHER EXPANSION OF CLINICAL STUDY INVESTIGATING COOLING OF STROKE PATIENTS

Life Recovery Systems has been granted approval by the US Food and Drug Administration (FDA) to further expand its clinical study of the use of the ThermoSuit® System in the treatment of ischemic stroke (the “SISCO” study, which is being conducted under an investigational device exemption (IDE)). Under the revised IDE up to six hospitals are now allowed to participate in the study. Sites which have joined the study include Tulane Medical Center, PRISMA Health/USC, Geisinger Medical Center, and Geisinger Wyoming Valley Medical Center. The company is seeking two additional sites to help with the investigation.

According to Dr. Robert Schock, Vice President of R&D for the firm, “We continue to be pleased with the results we have seen thus far as our rapid cooling treatment has been investigated in victims of stroke. Preliminary data predict that cooling will be most effective if provided close to the time of reperfusion. Enrollments have been slow during the COVID pandemic, but with COVID rates decreasing and study sites increasing we expect the pace of the study to pick up significantly” Patients in the trial are being cooled while under sedation, with the intent of reaching a state of therapeutic hypothermia in approximately 30 to 40 minutes.

The ThermoSuit System uses direct liquid contact with the patient to reduce core body temperature. A thin film of ice water is circulated over the patient’s body until the temperature reaches a pre-set limit, at which point the water is automatically removed from the suit. The system is easily set up by nurses or technicians in minutes and cools to a therapeutic temperature of 33˚C in about 30 to 40 minutes. The patient is then removed from the suit and remains cold for hours, without the need for further maintenance, allowing unencumbered access for subsequent imaging or treatment.

A similar trial investigating the cooling of victims of acute myocardial infarction (“CHIPAHA”) has also received IDE approval, and will be pursued at a later date, using input obtained from the SISCO stroke trial.

About Life Recovery Systems

Founded in 2003, Life Recovery Systems focuses on ground-breaking, innovative medical devices for the emergency medical care market. Its mission is to save and preserve the quality of lives. Its first product, the ThermoSuit System, was developed with the assistance of NIH NHLBI funding to provide physicians and nurses with a safe, convenient, and extremely rapid method for cooling patients. It has received FDA 510(k) clearance for “temperature reduction in patients where clinically indicated, e.g. in hyperthermic patients.” It won a Medical Design Excellence Award in 2009, and multicenter clinical results were published in the Journal Resuscitation in 2010. Headquartered in Kinnelon, NJ, Life Recovery Systems also has offices in Alexandria, LA. www.life-recovery.com.

Contact: Robert Schock
info@life-recovery.com
Phone: 973-283-2800